Seeking Novel CNS Indications and Mechanistic Pathways for RIPK1 Inhibition

A global pharmaceutical company has developed a CNS-penetrant receptor-interacting protein kinase 1 (RIPK1) inhibitor and is seeking partnerships with expertise in RIPK1's role in human pathophysiology. The company aims to identify promising disease indications for further development of the inhibitor.

 Approaches of interest:

• Identification of CNS disease indications driven by the RIPK1 pathway.
• Focus on both genetic rare diseases and common diseases, with an emphasis on patient stratification.
• Exploration of symptoms/pathophysiology linked to increased RIPK1 kinase activity.
• Investigation of pathways modulated by RIPK1 inhibitors beyond inflammation and necroptosis.
• Incorporation of RIPK3 and MLKL kinases involved in RIPK1 signaling.

Out of scope: 

• Indications already in clinical trials (e.g., ALS, MS, IBD).
  Research related to ischemic stroke, Krabbe disease, and Niemann-Pick disease type C.

Developmental stage of interest: Research at basic to late preclinical stages, with a preference for opportunities that have in vivo validation.

The company is open to various collaboration opportunities, including licensing, project/PhD funding, and research partnerships.

Please note: Faculty and researchers interested in applying for these opportunities based on technologies developed or disclosed at Vanderbilt must submit their proposals through our Center for Technology Transfer and Commercialization.